II
119THCONGRESS
1
STSESSION S. 233
To amend the Office of National Drug Control Policy Reauthorization Act
of 2006 to modify the authority of the Office of National Drug Control
Policy with respect to the World Anti-Doping Agency, and for other
purposes.
IN THE SENATE OF THE UNITED STATES
JANUARY23, 2025
Mrs. B
LACKBURN (for herself, Mr. VANHOLLEN, Mrs. CAPITO, Mr.
B
LUMENTHAL, and Mr. WICKER) introduced the following bill; which was
read twice and referred to the Committee on Commerce, Science, and
Transportation
A BILL
To amend the Office of National Drug Control Policy Reau-
thorization Act of 2006 to modify the authority of the
Office of National Drug Control Policy with respect to
the World Anti-Doping Agency, and for other purposes.
Be it enacted by the Senate and House of Representa-1
tives of the United States of America in Congress assembled, 2
SECTION 1. SHORT TITLE. 3
This Act may be cited as the ‘‘Restoring Confidence 4
in the World Anti-Doping Agency Act of 2025’’. 5
VerDate Sep 11 2014 18:01 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00001 Fmt 6652 Sfmt 6201 E:\BILLS\S233.IS S233
ssavage on LAPJG3WLY3PROD with BILLS 2
•S 233 IS
SEC. 2. AUTHORITY OF NATIONAL DRUG CONTROL POLICY 1
WITH RESPECT TO THE WORLD ANTI-DOPING 2
AGENCY. 3
Section 701 of the Office of National Drug Control 4
Policy Reauthorization Act of 2006 (21 U.S.C. 2001) is 5
amended— 6
(1) in subsection (a)— 7
(A) by amending paragraph (1) to read as 8
follows: 9
‘‘(1) U
NITED STATES OLYMPIC AND 10
PARALYMPIC COMMITTEE .—The term ‘United States 11
Olympic and Paralympic Committee’ means the or-12
ganization established by chapter 2205 of title 36, 13
United States Code.’’; 14
(B) in paragraph (3), by striking ‘‘(36 15
U.S.C. 22501(b)(1))’’ and inserting ‘‘(36 16
U.S.C. 220501(b)(1))’’; 17
(C) by redesignating paragraphs (1) and 18
(3) as paragraphs (4) and (1), respectively, and 19
moving the paragraphs so as to appear in nu-20
meric order; and 21
(D) by inserting after paragraph (2) the 22
following: 23
‘‘(3) I
NDEPENDENT ATHLETE .—The term 24
‘independent athlete’ means an Olympic or 25
VerDate Sep 11 2014 18:01 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00002 Fmt 6652 Sfmt 6201 E:\BILLS\S233.IS S233
ssavage on LAPJG3WLY3PROD with BILLS 3
•S 233 IS
Paralympic athlete who does not serve, in any capac-1
ity— 2
‘‘(A) on the International Olympic Com-3
mittee; 4
‘‘(B) on the International Paralympic 5
Committee; 6
‘‘(C) at an international sports federation 7
recognized by the International Olympic Com-8
mittee or the International Paralympic Com-9
mittee; 10
‘‘(D) on the United States Olympic and 11
Paralympic Committee; or 12
‘‘(E) at the World Anti-Doping Agency.’’; 13
(2) in subsection (b)— 14
(A) by striking ‘‘United States Olympic 15
Committee’’ each place it appears and inserting 16
‘‘United States Olympic and Paralympic Com-17
mittee’’; 18
(B) in paragraph (5), by striking the pe-19
riod at the end and inserting ‘‘; and’’; and 20
(C) by adding at the end the following: 21
‘‘(6) carry out responsibilities with respect to 22
the World Anti-Doping Agency, as described in sub-23
section (d).’’; and 24
(3) by adding at the end the following: 25
VerDate Sep 11 2014 18:01 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00003 Fmt 6652 Sfmt 6201 E:\BILLS\S233.IS S233
ssavage on LAPJG3WLY3PROD with BILLS 4
•S 233 IS
‘‘(d) AUTHORITYWITHRESPECT TO THE WORLD 1
A
NTI-DOPINGAGENCY.— 2
‘‘(1) I
N GENERAL.—The Office of National 3
Drug Control Policy, in consultation with the United 4
States Anti-Doping Agency, the United States Olym-5
pic and Paralympic Committee, and the Team USA 6
Athletes’ Commission, shall— 7
‘‘(A) use all available tools to ensure 8
that— 9
‘‘(i) the World Anti-Doping Agency 10
has a credible and independent governance 11
model that provides for fair representation 12
of the United States; 13
‘‘(ii) the World Anti-Doping Agency 14
fully implements all governance reforms, 15
including a proper conflict-of-interest pol-16
icy for all members of the Executive Com-17
mittee, the Foundation Board, and all rel-18
evant expert advisory groups, standing 19
committees, permanent special committees, 20
and working groups of the World Anti- 21
Doping Agency; and 22
‘‘(iii) independent athletes from the 23
United States and other democratic coun-24
tries, or representatives of such athletes, 25
VerDate Sep 11 2014 18:01 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00004 Fmt 6652 Sfmt 6201 E:\BILLS\S233.IS S233
ssavage on LAPJG3WLY3PROD with BILLS 5
•S 233 IS
have decision-making roles on the Execu-1
tive Committee and the Foundation Board, 2
and in all relevant expert advisory groups, 3
standing committees, permanent special 4
committees, and working groups, of the 5
World Anti-Doping Agency; 6
‘‘(B) demonstrate leadership within the 7
global community; 8
‘‘(C) have strict standards that work to-9
ward countering doping in every form, including 10
by countering systemic fraud through doping 11
involving— 12
‘‘(i) governmental law enforcement, 13
intelligence, or anti-doping institutions; 14
‘‘(ii) sporting organizations; or 15
‘‘(iii) athlete support personnel; and 16
‘‘(D) work collaboratively with democratic 17
countries. 18
‘‘(2) D
ETERMINATION.— 19
‘‘(A) I
N GENERAL.—Not later than 90 20
days after the date of the enactment of this 21
subsection, the Office of National Drug Control 22
Policy, in consultation with the United States 23
Anti-Doping Agency, the United States Olympic 24
and Paralympic Committee, and the Team USA 25
VerDate Sep 11 2014 18:01 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00005 Fmt 6652 Sfmt 6201 E:\BILLS\S233.IS S233
ssavage on LAPJG3WLY3PROD with BILLS 6
•S 233 IS
Athletes’ Commission, shall make a determina-1
tion as to whether the World Anti-Doping 2
Agency— 3
‘‘(i) has a credible and independent 4
governance model that provides for fair 5
representation of the United States; 6
‘‘(ii) fully implements all governance 7
reforms, including a proper conflict-of-in-8
terest policy described in paragraph 9
(1)(A)(ii); and 10
‘‘(iii) allows independent athletes from 11
the United States and other democratic 12
countries, or representatives of such ath-13
letes, to have decision-making roles on the 14
Executive Committee and the Foundation 15
Board, and in all relevant expert advisory 16
groups, standing committees, permanent 17
special committees, and working groups, of 18
the World Anti-Doping Agency. 19
‘‘(B) A
CCOUNTABILITY.—In the case of a 20
determination under subparagraph (A) that the 21
World Anti-Doping Agency does not have such 22
a governance model, has not fully implemented 23
such governance reforms, or has not allowed de-24
cision-making roles described in clause (iii) of 25
VerDate Sep 11 2014 18:01 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00006 Fmt 6652 Sfmt 6201 E:\BILLS\S233.IS S233
ssavage on LAPJG3WLY3PROD with BILLS 7
•S 233 IS
that subparagraph, the Office of National Drug 1
Control Policy, in consultation with the United 2
States Anti-Doping Agency, the United States 3
Olympic and Paralympic Committee, and the 4
Team USA Athletes’ Commission, shall— 5
‘‘(i) use all available tools to ensure 6
that the United States has fair representa-7
tion in the World Anti-Doping Agency, in-8
cluding— 9
‘‘(I) on the Executive Committee; 10
‘‘(II) on the Foundation Board; 11
and 12
‘‘(III) in all relevant expert advi-13
sory groups, standing committees, 14
permanent special committees, and 15
working groups of the World Anti- 16
Doping Agency; and 17
‘‘(ii) not later than 180 days after the 18
date on which the determination under 19
subparagraph (A) is made, issue a report 20
that describes the barriers to participation 21
and fair representation of the United 22
States on the Executive Committee, the 23
Foundation Board, and all relevant expert 24
advisory groups, standing committees, per-25
VerDate Sep 11 2014 18:01 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00007 Fmt 6652 Sfmt 6201 E:\BILLS\S233.IS S233
ssavage on LAPJG3WLY3PROD with BILLS 8
•S 233 IS
manent special committees, and working 1
groups of the World Anti-Doping Agency. 2
‘‘(3) V
OLUNTARY NONPAYMENT OF DUES .— 3
‘‘(A) I
N GENERAL.—In the case of a deter-4
mination under paragraph (2)(A) that the 5
World Anti-Doping Agency does not have a gov-6
ernance model that provides for fair representa-7
tion of the United States, has not fully imple-8
mented governance reforms, or has not allowed 9
decision-making roles described in clause (iii) of 10
that subparagraph, the Office of National Drug 11
Control Policy, in consultation with the appro-12
priate committees of Congress, may voluntarily 13
withhold up to the full amount of membership 14
dues to the World Anti-Doping Agency. 15
‘‘(B) A
PPROPRIATE COMMITTEES OF CON -16
GRESS DEFINED.—In this paragraph, the term 17
‘appropriate committees of Congress’ means— 18
‘‘(i) the Subcommittee on Consumer 19
Protection, Product Safety, and Data Se-20
curity of the Committee on Commerce, 21
Science, and Transportation of the Senate 22
(or a successor subcommittee); 23
‘‘(ii) the Subcommittee on Financial 24
Services and General Government of the 25
VerDate Sep 11 2014 18:01 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00008 Fmt 6652 Sfmt 6201 E:\BILLS\S233.IS S233
ssavage on LAPJG3WLY3PROD with BILLS 9
•S 233 IS
Committee on Appropriations of the Sen-1
ate (or a successor subcommittee); 2
‘‘(iii) the Subcommittee on Oversight 3
and Investigations of the Committee on 4
Energy and Commerce of the House of 5
Representatives (or a successor sub-6
committee); and 7
‘‘(iv) the Subcommittee on Financial 8
Services and General Government of the 9
Committee on Appropriations of the House 10
of Representatives (or a successor sub-11
committee). 12
‘‘(4) S
PENDING PLAN.—Not later than 30 days 13
before the Office of National Drug Control Policy 14
obligates funds to the World Anti-Doping Agency, 15
the Office of National Drug Control Policy shall sub-16
mit to the Committee on Appropriations of the Sen-17
ate and the Committee on Appropriations of the 18
House of Representatives a spending plan and expla-19
nation of proposed uses of such funds.’’. 20
Æ
VerDate Sep 11 2014 18:01 Feb 19, 2025 Jkt 059200 PO 00000 Frm 00009 Fmt 6652 Sfmt 6301 E:\BILLS\S233.IS S233
ssavage on LAPJG3WLY3PROD with BILLS